Hospital Regional Universitario de Málaga-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2023

  1. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

2021

  1. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry

    Rheumatology International, Vol. 39, Núm. 3, pp. 509-515

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: Results from BIOBADASER

    Arthritis Research and Therapy, Vol. 20, Núm. 1

2017

  1. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2015

  1. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

2011

  1. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology